Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders

A. Olivieri, I. Scortechini, D. Capelli, M. Montanari, M. Lucesole, G. Gini, M. Troiani, M. Offidani, A. Poloni, M. C. Masia, G. M. Raggetti, P. Leoni

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We compared the use of G-CSF plus EPO in a group of 32 multiple myeloma and lymphoma patients with historical controls receiving G-CSF alone. Haemopoietic reconstitution was significantly faster in patients receiving G-CSF + EPO (group B), with a median time of 10 days to achieve an ANC count >0.5 × 109/l, compared to 11 days in the historical group (A). The median duration of severe neutropenia (ANC count 20 × 109 and >50 × 109/l were achieved at days + 13 and + 17, respectively in group B, compared to days + 14 and + 24, respectively, in group A (P = 0.015, 0.002) patients. The transfusion requirement was reduced in group B, with 0 (0-6) RBC units and 1 (0-5) platelet unit transfused in group B vs 2 RBC (0-9) and 2 platelet units (0-8) in group A. Median days of fever, antibiotic therapy and hospital stay were reduced in group B (9.5 days vs 22). The mean cost of autotransplantation per group A patient was 23 988 Euro, compared with 18 394 Euro for a group B patient. Our study suggests that the EPO + G-CSF combination not only accelerates engraftment kinetics, but can also improve the clinical course of ASCT.

Original languageEnglish
Pages (from-to)693-702
Number of pages10
JournalBone Marrow Transplantation
Volume34
Issue number8
DOIs
Publication statusPublished - Oct 2004

Fingerprint

Lymphoproliferative Disorders
Stem Cell Transplantation
Erythropoietin
Granulocyte Colony-Stimulating Factor
Costs and Cost Analysis
Blood Platelets
Induced Hyperthermia
Autologous Transplantation
Neutropenia
Multiple Myeloma
Lymphoma
Length of Stay
Filgrastim
Anti-Bacterial Agents

Keywords

  • Autologous transplantation
  • Engraftment kinetics
  • Erythropoietin

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders. / Olivieri, A.; Scortechini, I.; Capelli, D.; Montanari, M.; Lucesole, M.; Gini, G.; Troiani, M.; Offidani, M.; Poloni, A.; Masia, M. C.; Raggetti, G. M.; Leoni, P.

In: Bone Marrow Transplantation, Vol. 34, No. 8, 10.2004, p. 693-702.

Research output: Contribution to journalArticle

Olivieri, A, Scortechini, I, Capelli, D, Montanari, M, Lucesole, M, Gini, G, Troiani, M, Offidani, M, Poloni, A, Masia, MC, Raggetti, GM & Leoni, P 2004, 'Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders', Bone Marrow Transplantation, vol. 34, no. 8, pp. 693-702. https://doi.org/10.1038/sj.bmt.1704643
Olivieri, A. ; Scortechini, I. ; Capelli, D. ; Montanari, M. ; Lucesole, M. ; Gini, G. ; Troiani, M. ; Offidani, M. ; Poloni, A. ; Masia, M. C. ; Raggetti, G. M. ; Leoni, P. / Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders. In: Bone Marrow Transplantation. 2004 ; Vol. 34, No. 8. pp. 693-702.
@article{f0331479adb443bfbf65749d7ca1bf71,
title = "Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders",
abstract = "We compared the use of G-CSF plus EPO in a group of 32 multiple myeloma and lymphoma patients with historical controls receiving G-CSF alone. Haemopoietic reconstitution was significantly faster in patients receiving G-CSF + EPO (group B), with a median time of 10 days to achieve an ANC count >0.5 × 109/l, compared to 11 days in the historical group (A). The median duration of severe neutropenia (ANC count 20 × 109 and >50 × 109/l were achieved at days + 13 and + 17, respectively in group B, compared to days + 14 and + 24, respectively, in group A (P = 0.015, 0.002) patients. The transfusion requirement was reduced in group B, with 0 (0-6) RBC units and 1 (0-5) platelet unit transfused in group B vs 2 RBC (0-9) and 2 platelet units (0-8) in group A. Median days of fever, antibiotic therapy and hospital stay were reduced in group B (9.5 days vs 22). The mean cost of autotransplantation per group A patient was 23 988 Euro, compared with 18 394 Euro for a group B patient. Our study suggests that the EPO + G-CSF combination not only accelerates engraftment kinetics, but can also improve the clinical course of ASCT.",
keywords = "Autologous transplantation, Engraftment kinetics, Erythropoietin",
author = "A. Olivieri and I. Scortechini and D. Capelli and M. Montanari and M. Lucesole and G. Gini and M. Troiani and M. Offidani and A. Poloni and Masia, {M. C.} and Raggetti, {G. M.} and P. Leoni",
year = "2004",
month = "10",
doi = "10.1038/sj.bmt.1704643",
language = "English",
volume = "34",
pages = "693--702",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders

AU - Olivieri, A.

AU - Scortechini, I.

AU - Capelli, D.

AU - Montanari, M.

AU - Lucesole, M.

AU - Gini, G.

AU - Troiani, M.

AU - Offidani, M.

AU - Poloni, A.

AU - Masia, M. C.

AU - Raggetti, G. M.

AU - Leoni, P.

PY - 2004/10

Y1 - 2004/10

N2 - We compared the use of G-CSF plus EPO in a group of 32 multiple myeloma and lymphoma patients with historical controls receiving G-CSF alone. Haemopoietic reconstitution was significantly faster in patients receiving G-CSF + EPO (group B), with a median time of 10 days to achieve an ANC count >0.5 × 109/l, compared to 11 days in the historical group (A). The median duration of severe neutropenia (ANC count 20 × 109 and >50 × 109/l were achieved at days + 13 and + 17, respectively in group B, compared to days + 14 and + 24, respectively, in group A (P = 0.015, 0.002) patients. The transfusion requirement was reduced in group B, with 0 (0-6) RBC units and 1 (0-5) platelet unit transfused in group B vs 2 RBC (0-9) and 2 platelet units (0-8) in group A. Median days of fever, antibiotic therapy and hospital stay were reduced in group B (9.5 days vs 22). The mean cost of autotransplantation per group A patient was 23 988 Euro, compared with 18 394 Euro for a group B patient. Our study suggests that the EPO + G-CSF combination not only accelerates engraftment kinetics, but can also improve the clinical course of ASCT.

AB - We compared the use of G-CSF plus EPO in a group of 32 multiple myeloma and lymphoma patients with historical controls receiving G-CSF alone. Haemopoietic reconstitution was significantly faster in patients receiving G-CSF + EPO (group B), with a median time of 10 days to achieve an ANC count >0.5 × 109/l, compared to 11 days in the historical group (A). The median duration of severe neutropenia (ANC count 20 × 109 and >50 × 109/l were achieved at days + 13 and + 17, respectively in group B, compared to days + 14 and + 24, respectively, in group A (P = 0.015, 0.002) patients. The transfusion requirement was reduced in group B, with 0 (0-6) RBC units and 1 (0-5) platelet unit transfused in group B vs 2 RBC (0-9) and 2 platelet units (0-8) in group A. Median days of fever, antibiotic therapy and hospital stay were reduced in group B (9.5 days vs 22). The mean cost of autotransplantation per group A patient was 23 988 Euro, compared with 18 394 Euro for a group B patient. Our study suggests that the EPO + G-CSF combination not only accelerates engraftment kinetics, but can also improve the clinical course of ASCT.

KW - Autologous transplantation

KW - Engraftment kinetics

KW - Erythropoietin

UR - http://www.scopus.com/inward/record.url?scp=6444232245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6444232245&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704643

DO - 10.1038/sj.bmt.1704643

M3 - Article

C2 - 15300235

AN - SCOPUS:6444232245

VL - 34

SP - 693

EP - 702

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -